Loading...
603233 logo

DaShenLin Pharmaceutical Group Co., Ltd.SHSE:603233 Stock Report

Market Cap CN¥18.4b
Share Price
CN¥16.19
CN¥24.49
33.9% undervalued intrinsic discount
1Y-6.5%
7D-2.2%
1D
Portfolio Value
View

DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 Stock Report

Market Cap: CN¥18.4b

603233 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

DaShenLin Pharmaceutical Group Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for DaShenLin Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥16.19
52 Week HighCN¥21.78
52 Week LowCN¥15.34
Beta0.62
1 Month Change-13.52%
3 Month Change-17.69%
1 Year Change-6.47%
3 Year Change-38.89%
5 Year Change-58.71%
Change since IPO22.59%

Recent News & Updates

Recent updates

Analysis Article Mar 14

We Think DaShenLin Pharmaceutical Group (SHSE:603233) Can Stay On Top Of Its Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Feb 14

Potential Upside For DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Not Without Risk

DaShenLin Pharmaceutical Group Co., Ltd.'s ( SHSE:603233 ) price-to-earnings (or "P/E") ratio of 20.5x might make it...
Analysis Article Sep 30

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd.'s ( SHSE:603233 ) price-to-earnings (or "P/E") ratio of 18.6x might make it...
Analysis Article Sep 03

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group Co., Ltd. ( SHSE:603233 ) just released its latest quarterly report and things are not...
Analysis Article Aug 20

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Analysis Article Jun 17

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

DaShenLin Pharmaceutical Group Co., Ltd. ( SHSE:603233 ) shareholders that were waiting for something to happen have...
Analysis Article Jun 09

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article May 21

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, DaShenLin Pharmaceutical Group fair value estimate is CN¥31.80...
Analysis Article May 06

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Soft earnings didn't appear to concern DaShenLin Pharmaceutical Group Co., Ltd.'s ( SHSE:603233 ) shareholders over the...
Analysis Article Apr 09

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analysis Article Mar 17

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

With a price-to-earnings (or "P/E") ratio of 19.6x DaShenLin Pharmaceutical Group Co., Ltd. ( SHSE:603233 ) may be...

Shareholder Returns

603233CN Consumer RetailingCN Market
7D-2.2%0.3%-2.5%
1Y-6.5%-13.0%32.1%

Return vs Industry: 603233 exceeded the CN Consumer Retailing industry which returned -13% over the past year.

Return vs Market: 603233 underperformed the CN Market which returned 32.1% over the past year.

Price Volatility

Is 603233's price volatile compared to industry and market?
603233 volatility
603233 Average Weekly Movement4.0%
Consumer Retailing Industry Average Movement5.0%
Market Average Movement6.6%
10% most volatile stocks in CN Market10.2%
10% least volatile stocks in CN Market4.3%

Stable Share Price: 603233 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 603233's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199941,141Guoqiang Kewww.dslyy.com

DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.

DaShenLin Pharmaceutical Group Co., Ltd. Fundamentals Summary

How do DaShenLin Pharmaceutical Group's earnings and revenue compare to its market cap?
603233 fundamental statistics
Market capCN¥18.44b
Earnings (TTM)CN¥1.29b
Revenue (TTM)CN¥27.52b
14.3x
P/E Ratio
0.7x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
603233 income statement (TTM)
RevenueCN¥27.52b
Cost of RevenueCN¥18.03b
Gross ProfitCN¥9.49b
Other ExpensesCN¥8.20b
EarningsCN¥1.29b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)1.13
Gross Margin34.49%
Net Profit Margin4.67%
Debt/Equity Ratio33.3%

How did 603233 perform over the long term?

See historical performance and comparison

Dividends

6.1%
Current Dividend Yield
74%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/03 21:50
End of Day Share Price 2026/06/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DaShenLin Pharmaceutical Group Co., Ltd. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Qianyi LiChina International Capital Corporation Limited
Sophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)
Binbin ZhangCitic Securities Co., Ltd.